CVS Health Corp.

Reflecting the growing willingness among biopharma executives to openly voice concerns about the Trump Administration’s policies, Eli Lilly CEO David Ricks started out the firm’s first quarter earning

Eli Lilly has made significant headway in obesity in the first quarter of 2025, recording big year-over-year revenue gains from the GIP/GLP-1 receptor agonist Zepbound (tirzepatide) and successful Pha

Drug and biologic product-related enforcement is expected to remain strong during the next Trump Administration, although the focus could shift compared to the Biden Administration. Imported ingredien

Because the Inflation Reduction Act (IRA) is making significant changes to the Medicare Part D benefit structure next year, industry watchers have been bracing for US Centers for Medicare and Medicaid